TLDR:
- CMND partners with PLRZ to develop intranasal MEAI hydrogel for CNS delivery
- Clearmind targets higher MEAI bioavailability with Polyrizon’s nasal hydrogel tech
- CMND signs related-party deal to support addiction and CNS clinical programs
- Intranasal MEAI aims to extend nasal residence time and improve patient usability
- Clearmind uses MI61-101 exemptions for valuation and minority approval requirements
Clearmind Medicine (CMND) trades around $1.51 as it signs a development deal for intranasal MEAI delivery. The company partners with Polyrizon to build a hydrogel formulation that targets higher bioavailability. The agreement supports ongoing programs for addiction-related and central nervous system disorders.
Intranasal hydrogel work targets stronger MEAI delivery
Clearmind contracts Polyrizon to apply its intranasal hydrogel technology to the MEAI compound. The parties aim to produce an optimized nasal formulation designed for more consistent exposure. As a result, the program prioritizes delivery performance alongside clinical readiness.
The collaboration targets longer nasal residence time through gel-like mechanisms that support absorption. It also targets more direct CNS delivery to improve therapeutic potential across targeted indications. In addition, the design emphasizes patient usability to support real-world administration.
The agreement also builds flexibility around MEAI’s physicochemical properties during formulation work. This approach allows iterative tuning of viscosity, retention, and release behavior across development steps. Therefore, the partners position formulation engineering as a core lever for performance improvement.
Delivery goals focus on CNS access and patient experience
Intranasal delivery can bypass first-pass metabolism, which can limit oral exposure and consistency. This route can also deliver faster absorption, which may support quicker onset profiles. Furthermore, a lower effective dose may become feasible when exposure improves through optimized delivery.
Clearmind frames the program around a non-hallucinogenic neuroplastogen designed for addiction-related disorders and other CNS conditions. The company also identifies weight loss as a potential application area in its broader development scope. Delivery optimization supports multiple future program directions.
Polyrizon’s platform uses nasal spray hydrogels that can remain at the deposition site longer. That retention supports prolonged contact time with nasal tissues and can help sustain absorption. In turn, the project aims to pair retention with targeted delivery features tailored for MEAI.
Related-party structure uses MI61-101 exemptions
Clearmind classifies Polyrizon as a related party under Canadian rules tied to MI61-101. The company treats the agreement as a related-party transaction within that framework. It therefore relies on available exemptions for formal valuation and minority approval requirements.
Clearmind cites exemptions that apply when transaction terms and thresholds meet defined criteria. This structure streamlines governance steps while keeping disclosures aligned with the applicable rulebook. The company still emphasizes compliance with required procedural standards.
The related-party disclosure also signals a focus on transparency around decision structure and oversight. Clearmind positions the arrangement as a development-focused transaction rather than a financing event. As a result, the agreement centers on technical deliverables and formulation milestones.
Clinical-stage positioning and product context
Clearmind operates as a clinical-stage biotech focused on neuroplastogen-derived therapeutics. The company targets under-treated health problems and prioritizes regulated medicine pathways. It positions MEAI as its lead proprietary compound within that pipeline.
The company also describes a broader psychedelic-derived therapeutics strategy while emphasizing non-hallucinogenic candidates. It aims to develop compounds for alcohol use disorder and related addiction areas. At the same time, it explores additional CNS conditions as future opportunities.
Clearmind reports an intellectual property base that includes nineteen patent families and 31 granted patents. It states it plans to pursue additional patents when warranted across its compound portfolio. This posture supports defensibility as the pipeline advances toward further validation.
Polyrizon platform background and strategic fit
Polyrizon develops intranasal hydrogel technologies delivered through nasal sprays and related delivery systems. It also develops barrier-style hydrogels designed to shield the nasal cavity from irritants and allergens. This focus creates a base for drug delivery work that depends on adhesion and retention.
The company describes its Capture and Contain hydrogel approach as a containment barrier within the nasal cavity. It also develops bioadhesion features to extend retention time at the nasal deposition site. These attributes align with Clearmind’s goals for longer residence time and better absorption.
Polyrizon also works on an earlier-stage approach for delivering active pharmaceutical ingredients intranasally. This pipeline includes technology aimed at trapping and targeting compounds for local and systemic effects. Therefore, the partnership aligns platform development with a named drug candidate program.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
